The United States stock market has recently experienced a surge, with major indices like the Dow Jones and Nasdaq Composite showing significant gains amid optimism over reduced China tariffs and ...

Scotiabank analyst Greg Harrison lowered the firm’s price target on Travere Therapeutics (TVTX) to $30 from $32 and keeps an Outperform rating ...

Novartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.

Canaccord analyst Edward Nash raised the firm’s price target on Travere Therapeutics (TVTX) to $47 from $45 and keeps a Buy rating on the ...

Travere Therapeutics (NASDAQ:TVTX – Free Report) had its target price lifted by Canaccord Genuity Group from $45.00 to $47.00 in a research note issued to investors on Thursday morning ...

The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new employee’s continued service relationship with Travere through the applicable ...

Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) – Wedbush issued their Q1 2026 EPS estimates for shares of Travere Therapeutics in a research report issued on Wednesday, April 16th.

Ratings for Travere Therapeutics (NASDAQ:TVTX) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick ...

The latest analyst rating for Travere Therapeutics (NASDAQ:TVTX) was provided by Guggenheim, and Travere Therapeutics reiterated their buy rating. The last upgrade for Travere Therapeutics Inc ...

BOSTON -- Patients with focal segmental glomerulosclerosis (FSGS) achieved some degree of proteinuria remission more often ...

Scotiabank analyst Greg Harrison lowered the firm’s price target on Travere Therapeutics (TVTX) to $30 from $32 and keeps an Outperform rating on the shares.The company recently presented ...